Keyphrases
Peripheral Blood
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Programmed Death-ligand 1 (PD-L1)
100%
Poor Clinical Outcomes
100%
CD4+ T Cells
100%
Non-small Cell Lung Cancer Patients
22%
Effective Method
11%
Tumor Growth
11%
Predictive Value
11%
Overall Survival
11%
Blood Samples
11%
High-level Expression
11%
Clinical Response
11%
T Cells
11%
Tumor Cells
11%
T Cell Exhaustion
11%
Prognostic Value
11%
Flow Cytometric Analysis
11%
Tumor Antigen
11%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
11%
Progression-free Survival
11%
Surface Expression
11%
Antigen-presenting Cells
11%
Non-invasive Method
11%
Blocking Antibodies
11%
Initial Diagnosis
11%
Prognostic Biomarker
11%
Recurrent Non-small Cell Lung Cancer
11%
Predictive Biomarker
11%
Pembrolizumab
11%
Effective Cancer Therapies
11%
Anti-PD-1
11%
Peripheral CD4+ T Cells
11%
Nivolumab
11%
Immune Checkpoint
11%
Medicine and Dentistry
Programmed Cell Death
100%
Non Small Cell Lung Cancer
100%
T-Helper Cell
100%
T Cell
25%
Biological Marker
12%
Flow Cytometry
12%
Tumor Progression
12%
Overall Survival
12%
Tumor Cell
12%
Progression Free Survival
12%
Tumor Antigen
12%
Cancer Therapy
12%
Blocking Antibody
12%
Antigen Presenting Cell
12%
Immunology and Microbiology
T-Helper Cell
100%
Programmed Cell Death 1
100%
T Cell
25%
Programmed Death-Ligand 1
25%
Surface Property
12%
Tumor Cell
12%
Tumor Antigen
12%
Overall Survival
12%
Blocking Antibody
12%
Progression Free Survival
12%
Antigen Presenting Cell
12%
Nivolumab
12%
Pembrolizumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Programmed Cell Death
100%
Biological Marker
12%
Malignant Neoplasm
12%
Flow Cytometry
12%
Neoplasm
12%
Tumor Growth
12%
Progression Free Survival
12%
Overall Survival
12%
Blocking Antibody
12%
Pembrolizumab
12%
Nivolumab
12%